Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
Authors
Keywords
-
Journal
EUROPEAN HEART JOURNAL
Volume 43, Issue 6, Pages 474-484
Publisher
Oxford University Press (OUP)
Online
2021-11-01
DOI
10.1093/eurheartj/ehab777
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage
- (2021) Peter Kolkhof et al. AMERICAN JOURNAL OF NEPHROLOGY
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
- (2021) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Type 2 Diabetes Mellitus and Impact of Heart Failure on Prognosis Compared to Other Cardiovascular Diseases
- (2020) Bochra Zareini et al. Circulation-Cardiovascular Quality and Outcomes
- Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
- (2020) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Serum potassium and heart failure: association, causation, and clinical implications
- (2020) Dimitrios Sfairopoulos et al. HEART FAILURE REVIEWS
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone
- (2020) Rajiv Agarwal et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of MajorAdverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
- (2019) Thomas A. Zelniker et al. CIRCULATION
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
- (2019) Brendon L Neuen et al. Lancet Diabetes & Endocrinology
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- (2016) Piotr Ponikowski et al. EUROPEAN HEART JOURNAL
- GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration
- (2014) Andrew S. Levey et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End-Stage Renal Disease and Mortality
- (2014) Josef Coresh et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
- (2013) Linda F. Fried et al. NEW ENGLAND JOURNAL OF MEDICINE
- Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis
- (2012) Caroline S Fox et al. LANCET
- Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
- (2012) Hans-Henrik Parving et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search